QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
Log in
NASDAQ:ZYNE

Zynerba Pharmaceuticals Stock Forecast, Price & News

$4.66
+0.17 (+3.79 %)
(As of 03/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.53
Now: $4.66
$4.80
50-Day Range
$3.45
MA: $4.49
$8.76
52-Week Range
$2.55
Now: $4.66
$9.00
Volume1.82 million shs
Average Volume7.51 million shs
Market Capitalization$137.19 million
P/E RatioN/A
Dividend YieldN/A
Beta2.83
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder; is in Phase II clinical trial for treating pediatric behavioral and emotional symptoms of 22q11.2 deletion syndrome; and to treat children and adolescent patients with fragile X syndrome. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.
Zynerba Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZYNE
CUSIPN/A
Phone484-581-7505
Employees28
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$90,000.00
Book Value$3.26 per share

Profitability

Net Income$-32,940,000.00

Miscellaneous

Market Cap$137.19 million
Next Earnings Date3/9/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.35 out of 5 stars

Medical Sector

645th out of 1,965 stocks

Pharmaceutical Preparations Industry

322nd out of 772 stocks

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$4.66
+0.17 (+3.79 %)
(As of 03/1/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZYNE News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYNE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zynerba Pharmaceuticals (NASDAQ:ZYNE) Frequently Asked Questions

Is Zynerba Pharmaceuticals a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zynerba Pharmaceuticals stock.
View analyst ratings for Zynerba Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Zynerba Pharmaceuticals?

Wall Street analysts have given Zynerba Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zynerba Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals saw a drop in short interest in the month of February. As of February 12th, there was short interest totaling 3,200,000 shares, a drop of 22.5% from the January 28th total of 4,130,000 shares. Based on an average trading volume of 4,870,000 shares, the days-to-cover ratio is currently 0.7 days.
View Zynerba Pharmaceuticals' Short Interest
.

When is Zynerba Pharmaceuticals' next earnings date?

Zynerba Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Zynerba Pharmaceuticals
.

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) posted its earnings results on Monday, November, 9th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.12.
View Zynerba Pharmaceuticals' earnings history
.

How has Zynerba Pharmaceuticals' stock price been impacted by COVID-19?

Zynerba Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ZYNE stock has increased by 19.8% and is now trading at $4.66.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ZYNE?

5 brokers have issued 12 month price objectives for Zynerba Pharmaceuticals' stock. Their forecasts range from $8.00 to $26.00. On average, they anticipate Zynerba Pharmaceuticals' share price to reach $15.40 in the next twelve months. This suggests a possible upside of 230.5% from the stock's current price.
View analysts' price targets for Zynerba Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Zynerba Pharmaceuticals' key executives?

Zynerba Pharmaceuticals' management team includes the following people:
  • Mr. Armando Anido M.B.A., MBA, Chairman & CEO (Age 63, Pay $956.42k)
  • Ms. Terri B. Sebree, Pres (Age 63, Pay $715.88k)
  • Mr. James E. Fickenscher, CFO, VP of Corp. Devel. & Treasurer (Age 57, Pay $596.62k)
  • Mr. William C. Roberts, VP of Investor Relations & Corp. Communications (Age 52)
  • Ms. Suzanne M. Hanlon, Sec., VP & Gen. Counsel (Age 64)
  • Dr. Joseph Palumbo, Chief Medical Officer

Who are some of Zynerba Pharmaceuticals' key competitors?

What other stocks do shareholders of Zynerba Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include (CGC), Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Shopify (SHOP) and Micron Technology (MU).

When did Zynerba Pharmaceuticals IPO?

(ZYNE) raised $42 million in an initial public offering (IPO) on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

What is Zynerba Pharmaceuticals' stock symbol?

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

Who are Zynerba Pharmaceuticals' major shareholders?

Zynerba Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include ETF Managers Group LLC (6.16%), AdvisorShares Investments LLC (2.07%), BlackRock Inc. (1.38%), JPMorgan Chase & Co. (0.78%), Renaissance Technologies LLC (0.49%) and Penserra Capital Management LLC (0.44%).
View institutional ownership trends for Zynerba Pharmaceuticals
.

Which institutional investors are selling Zynerba Pharmaceuticals stock?

ZYNE stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, and Northern Trust Corp.
View insider buying and selling activity for Zynerba Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Zynerba Pharmaceuticals stock?

ZYNE stock was purchased by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, AdvisorShares Investments LLC, Renaissance Technologies LLC, Penserra Capital Management LLC, Davy Global Fund Management Ltd, BlackRock Inc., JPMorgan Chase & Co., and Bank of New York Mellon Corp.
View insider buying and selling activity for Zynerba Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Zynerba Pharmaceuticals?

Shares of ZYNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zynerba Pharmaceuticals' stock price today?

One share of ZYNE stock can currently be purchased for approximately $4.66.

How much money does Zynerba Pharmaceuticals make?

Zynerba Pharmaceuticals has a market capitalization of $137.19 million and generates $90,000.00 in revenue each year. The company earns $-32,940,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis.

How many employees does Zynerba Pharmaceuticals have?

Zynerba Pharmaceuticals employs 28 workers across the globe.

What is Zynerba Pharmaceuticals' official website?

The official website for Zynerba Pharmaceuticals is www.zynerba.com.

Where are Zynerba Pharmaceuticals' headquarters?

Zynerba Pharmaceuticals is headquartered at 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333.

How can I contact Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The company can be reached via phone at 484-581-7505 or via email at investorrelations[email protected]


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.